StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$29.98−2.34 (-7.24%)

Close on Nov 17, 2026Market cap $352.37MP/E –Yield –

Surrozen cash

Cash and short-term investments held at the end of each period.

Surrozen's cash was $102.04M at Jun 30, 2026. For fiscal 2025 it was $89.25M, up 153.2% from the year before. The highest annual figure on record is $123.50M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$89.25M+153.2%
FY2024Dec 31, 2024$35.25M-4.0%
FY2023Dec 31, 2023$36.73M-51.5%
FY2022Dec 31, 2022$75.80M-38.6%
FY2021Dec 31, 2021$123.50M+149.1%
FY2020Dec 31, 2020$49.59M+68.0%
FY2019Dec 31, 2019$29.51M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$102.04M+12.9%
Q1 FY2026Mar 31, 2026$106.91M+5.2%
Q4 FY2025Dec 31, 2025$89.25M+153.2%
Q3 FY2025Sep 30, 2025$81.34M+162.3%
Q2 FY2025Jun 30, 2025$90.39M+139.3%
Q1 FY2025Mar 31, 2025$101.65M+176.7%
Q4 FY2024Dec 31, 2024$35.25M-18.8%
Q3 FY2024Sep 30, 2024$31.01M-41.9%
Q2 FY2024Jun 30, 2024$37.77M-38.8%
Q4 FY2023Dec 31, 2023$36.73M-51.5%
Q3 FY2023Sep 30, 2023$43.40M-44.6%
Q2 FY2023Jun 30, 2023$53.40M-42.4%
Q1 FY2023Mar 31, 2023$61.70M-33.3%
Q4 FY2022Dec 31, 2022$75.80M-38.6%
Q3 FY2022Sep 30, 2022$78.40M-28.8%
Q2 FY2022Jun 30, 2022$92.70M+391.8%
Q1 FY2022Mar 31, 2022$92.51M+295.3%
Q4 FY2021Dec 31, 2021$123.50M+149.1%
Q3 FY2021Sep 30, 2021$110.17M+87.0%
Q2 FY2021Jun 30, 2021$18.85M-36.1%
Q1 FY2021Mar 31, 2021$23.40M–
Q4 FY2020Dec 31, 2020$49.59M–
Q3 FY2020Sep 30, 2020$58.92M–
Q4 FY2019Dec 31, 2019$29.51M–

More Surrozen figures

See a number that looks wrong?